Medindia

X

Global Thought Leaders Outline Unmet Needs, Opportunities in Anxiety and Depression Market in New MedPredict Report

Tuesday, July 22, 2008 General News J E 4
Advertisement
SCOTTSDALE, Ariz., July 21 MedPredict Market Research, aglobal provider of pharmaceutical competitive intelligence and marketresearch, has published a new report providing critical strategic insight forpharma and biotech companies with a stake in the market for anxiety anddepression therapies.

In this report, entitled "MedPredict Thought Leader Insight & Analysis:Anxiety & Depression Q3 2008," a panel of physician experts from North Americaand Europe discuss the strengths and weaknesses of a variety of branded andnear-market antidepressants and anxiolytics.

"In our last report we highlighted three key unmet needs -- higher coreefficacy, more durable remissions and lower side effects," said Dr. JefferyBerk, MedPredict's president and one of the authors of the report. "This newreport identifies the characteristics that next-generation therapeutics willneed to go beyond those benefits and deliver enhanced cognition, reducedanhedonia, and relief from pain and fatigue." Some of the questions addressedby MedPredict's panel:

-- How will FDA's approval of Lilly's Cymbalta for neuropathic diabeticpain and fibromyalgia impact its use in depression? How important is a painindication in treatment of depression?

-- In this challenging regulatory and economic environment, what will newtherapeutics need to demonstrate to displace current usage of SSRIs, SRNIs andgeneric antidepressants? How should these studies be designed?

-- How do thought leaders view the strengths and weaknesses of Lilly'sCymbalta vs. Wyeth's Pristiq?

-- What are the differences in prescribing trends among psychiatristscompared with primary care physicians?

-- Which of the new molecules and mechanisms in development are mostpromising? The panel covers triple reuptake inhibitors, antipsychotics,MAOIs, Beta-3 agonists, nicotinic acetylcholine receptor agonists,NMDA/glutamatergics, GABA, CRH and more.

Companies/Partnerships discussed include: Abbott, AstraZeneca,Bristol-Myers Squibb, Forest/Lundbeck, Forest/Cypress/Pierre Fabre, Lilly,Lilly/Boehringer Ingelheim, Lundbeck/Takeda, Merck-Serono, Ono,Novartis/Servier, Pfizer, Sanofi-Aventis, Sepracor, Targacept/AstraZeneca,Wyeth, and others.

This report can be purchased by contacting MedPredict.

About MedPredict

MedPredict (http://www.medpredict.com) maintains a proprietary database ofover 1,000 global physician thought leaders, including 40+ specialties in 30+therapeutic categories. Based on primary interviews with these thoughtleaders, MedPredict publishes periodic reports in each category to keepclients up-to-date on emerging trends and competitive activity. The reportsinclude thought leader reactions to recent publications and medicalconferences, as well as clinical, regulatory and marketing activity.

SOURCE MedPredict
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Legal Momentum Applauds Senators Biden and Brownba...
S
Annual Minnesota State Open Pro-Am Tournament to B...